Key clinical point: An additional COVID-19 vaccine dose (AddDose) had no effect on rheumatoid arthritis (RA) disease activity, regardless of whether patients withheld or continued disease-modifying antirheumatic drugs (DMARD).
Major finding: The mean RA Disease Activity Index-5 was not significantly different pre- vs. post-AddDose (3.20 vs. 3.25; P = .51), with no difference observed among patients who withheld at least 1 DMARD or those who continued all DMARDs.
Study details: This was a prospective observational study including 71 patients with RA who had previously received either 2 doses of an mRNA COVID-19 vaccine or 1 dose of an adenovirus vector COVID-19 vaccine and planned for an AddDose.
Disclosures: ModernaTx supported Brigham and Women’s Hospital for an Investigator Sponsored Study, with additional support received from the US National Institutes of Health . The authors declared serving as scientific advisory board members or receiving research support and consulting fees from various sources, including ModernaTx.
Source: Tedeschi SK et al. Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine. Ann Rheum Dis. 2022 (Feb 15). Doi: 10.1136/annrheumdis-2022-222232